MRNA Moderna: Enterprise Value-to-Revenue Multiple

Moderna (MRNA) - corporate logo

Moderna, Inc. (MRNA) leverages its leadership in mRNA technologies to develop RSV vaccines and oncology drugs. The price-to-sales multiple on the GURU.Markets terminal line chart confirms the asset's dynamics, where the value 31568.75 reflects the current magnitude. Innovation centers in the US and Europe ensure stability, while strategic audits of external contractors minimize risks associated with outsourcing production.

MRNA: Moderna, Inc. Enterprise Value-to-Revenue Ratio 11/23/2025 - 11/20/2026

MRNA (modernatx.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Fundamental company valuation:Moderna, Inc., MRNA
Manufactured product of Moderna, Inc.

Moderna, Inc. (MRNA) is integrating ESG standards into the production of mRNA vaccines, optimizing the environmental footprint of its plants to ensure global healthcare accessibility. This Enterprise Value to Sales ratio allows for an assessment of the total business value without the influence of debt load, comparing the market price of assets with actual sales volume. The trend in the Enterprise Value to Sales ratio helps determine the fair cost of capital and identify overvaluation risks amid shifting demand.